vs
ALEXANDERS INC（ALX）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
ALEXANDERS INC的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.6倍（$53.3M vs $33.4M），ALEXANDERS INC同比增速更快（-4.7% vs -23.8%），过去两年Ginkgo Bioworks Holdings, Inc.的营收复合增速更高（-6.2% vs -6.9%）
亚历山大公司是一家房地产投资信托企业，在纽约大都会区持有七处物业，包括彭博有限合伙企业总部所在地列克星敦大道731号。该公司由乔治·法卡斯和路易斯·施瓦德伦于1928年创立，目前由沃那多房产信托控股。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
ALX vs DNA — 直观对比
营收规模更大
ALX
是对方的1.6倍
$33.4M
营收增速更快
ALX
高出19.1%
-23.8%
两年增速更快
DNA
近两年复合增速
-6.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.3M | $33.4M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | — | -211.9% |
| 净利率 | — | — |
| 营收同比 | -4.7% | -23.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.75 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALXDNA
| Q4 25 | $53.3M | $33.4M | ||
| Q3 25 | $53.4M | $38.8M | ||
| Q2 25 | $51.6M | $49.6M | ||
| Q1 25 | $54.9M | $48.3M | ||
| Q4 24 | $55.9M | $43.8M | ||
| Q3 24 | $55.7M | $89.0M | ||
| Q2 24 | $53.4M | $56.2M | ||
| Q1 24 | $61.4M | $37.9M |
净利润ALXDNA
| Q4 25 | — | — | ||
| Q3 25 | $6.0M | $-80.8M | ||
| Q2 25 | $6.1M | $-60.3M | ||
| Q1 25 | $12.3M | $-91.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.7M | $-56.4M | ||
| Q2 24 | $8.4M | $-217.2M | ||
| Q1 24 | $16.1M | $-165.9M |
营业利润率ALXDNA
| Q4 25 | — | -211.9% | ||
| Q3 25 | — | -231.8% | ||
| Q2 25 | — | -132.1% | ||
| Q1 25 | — | -184.1% | ||
| Q4 24 | — | -236.3% | ||
| Q3 24 | — | -62.0% | ||
| Q2 24 | — | -396.7% | ||
| Q1 24 | — | -469.1% |
净利率ALXDNA
| Q4 25 | — | — | ||
| Q3 25 | 11.2% | -207.9% | ||
| Q2 25 | 11.9% | -121.6% | ||
| Q1 25 | 22.4% | -188.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.0% | -63.3% | ||
| Q2 24 | 15.7% | -386.4% | ||
| Q1 24 | 26.2% | -437.3% |
每股收益（稀释后）ALXDNA
| Q4 25 | $0.75 | $-1.41 | ||
| Q3 25 | $1.16 | $-1.45 | ||
| Q2 25 | $1.19 | $-1.10 | ||
| Q1 25 | $2.40 | $-1.68 | ||
| Q4 24 | $2.39 | $-1.91 | ||
| Q3 24 | $1.30 | $-1.08 | ||
| Q2 24 | $1.63 | $-4.23 | ||
| Q1 24 | $3.14 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.2M | $422.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $109.2M | $508.6M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALXDNA
| Q4 25 | $128.2M | $422.6M | ||
| Q3 25 | $286.1M | $495.5M | ||
| Q2 25 | $313.0M | $559.4M | ||
| Q1 25 | $319.9M | $325.3M | ||
| Q4 24 | $338.5M | $561.6M | ||
| Q3 24 | $354.8M | $616.2M | ||
| Q2 24 | $410.9M | $730.4M | ||
| Q1 24 | $526.3M | $840.4M |
股东权益ALXDNA
| Q4 25 | $109.2M | $508.6M | ||
| Q3 25 | $128.3M | $559.8M | ||
| Q2 25 | $145.4M | $613.0M | ||
| Q1 25 | $163.1M | $647.4M | ||
| Q4 24 | $176.9M | $716.1M | ||
| Q3 24 | $190.7M | $797.9M | ||
| Q2 24 | $212.5M | $833.1M | ||
| Q1 24 | $230.1M | $987.3M |
总资产ALXDNA
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.4B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.4M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.7M |
| 自由现金流率自由现金流/营收 | — | -142.8% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ALXDNA
| Q4 25 | $73.4M | $-47.7M | ||
| Q3 25 | $-9.3M | $-31.6M | ||
| Q2 25 | $43.6M | $-40.3M | ||
| Q1 25 | $15.7M | $-51.5M | ||
| Q4 24 | $54.1M | $-42.4M | ||
| Q3 24 | $-5.0M | $-103.5M | ||
| Q2 24 | $11.5M | $-84.4M | ||
| Q1 24 | $16.8M | $-89.3M |
自由现金流ALXDNA
| Q4 25 | — | $-47.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-40.3M | ||
| Q1 25 | — | $-59.1M | ||
| Q4 24 | — | $-56.1M | ||
| Q3 24 | — | $-118.6M | ||
| Q2 24 | — | $-111.4M | ||
| Q1 24 | — | $-96.0M |
自由现金流率ALXDNA
| Q4 25 | — | -142.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -81.2% | ||
| Q1 25 | — | -122.4% | ||
| Q4 24 | — | -128.0% | ||
| Q3 24 | — | -133.2% | ||
| Q2 24 | — | -198.2% | ||
| Q1 24 | — | -252.9% |
资本支出强度ALXDNA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 17.7% |
现金转化率ALXDNA
| Q4 25 | — | — | ||
| Q3 25 | -1.55× | — | ||
| Q2 25 | 7.12× | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.75× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALX
暂无分部数据
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
